Govt's AEFI panel confirms first death after Covid-19 vaccination in India

The AEFI report also stated that vaccine product-related reactions are expected reactions that can be attributed to vaccination based on current scientific evidence

Topics
Coronavirus | Centre | Coronavirus Vaccine

ANI 

Coronavirus vaccine
Photo: Bloomberg

A 68-year-old man died due to anaphylaxis after he was administered a vaccine said the government panel that was studying vaccine side-effects (AEFI).

The AEFI committee's report stated that the 68-year-old died on March 8, 2021, due to anaphylaxis after being vaccinated.

In the other two anaphylaxis cases, the people, who were given vaccines on January 19 and 16, recovered after being admitted to a hospital.

The results of the causality assessment of 31 cases were approved by the National AEFI Committee on February 5 (five cases), March 9 (eight cases) and March 31, 2021 (18 cases) after thorough review and deliberations.

According to the report, "Of the 31 causally assessed cases, 18 were classified as having an inconsistent causal association to vaccination (coincidental - not linked to vaccination), 7 were classified as indeterminate, 3 cases were found to be vaccine product related, 1 was anxiety-related reaction and 2 cases were found to be unclassifiable."

"Unclassifiable events are events which have been investigated but there is not enough evidence for assigning a diagnosis due to missing crucial information. When this relevant information becomes available, the case may be reconsidered for causality assessment," the AEFI committee report said.

The AEFI report also stated that vaccine product-related reactions are expected reactions that can be attributed to vaccination based on current scientific evidence. Examples of such reactions are allergic reactions and anaphylaxis, etc.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Tue, June 15 2021. 13:54 IST
RECOMMENDED FOR YOU